We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 341

A patent landscape analysis: iPSCs

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • May 16 2013

There are several emerging technology clusters in the induced pluripotent stem cell (iPSC) space. Simon Elliot and I conducted a patent landscape

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Video interview: discussing the Supreme Court’s oral arguments in Myriad gene patenting case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 25 2013

Earlier this week, I had the opportunity to speak again with Colin O'Keefe of LXBN regarding last week's oral arguments in Association for Molecular

Federal Circuit finds Yaz patent obvious

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 25 2013

In Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court and held that Bayer's

Federal Circuit finds prosecution history disclaimer in enablement arguments

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 23 2013

In Biogen Idec, Inc. v. GlaxoSmithKline LLC, the Federal Circuit upheld a narrow claim interpretation based on prosecution history disclaimer. The

340B Drug Pricing Program: recent developments

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 18 2013

The 340B Drug Pricing Program (340B Program) continues to undergo a period of intense scrutiny and debate over how compliance with program rules is

CMS and OIG issue proposed rules modifying the stark exception and anti-kickback safe harbor for donation of EHR

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 17 2013

On April 10, 2013, the Centers for Medicare and Medicaid Services (CMS) and the Office of the Inspector General of the U.S. Department of Health and

Supreme Court oral arguments in ACLU Myriad gene patent case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 15 2013

On April 15, 2013, the Supreme Court heard oral arguments in one of the most controversial and publicized biotech patent cases-the "ACLUMyriad" gene

Personalized medicine and the gene patenting debate

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 15 2013

The transcript for today's Supreme Court oral argument in The Association for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398 (2013) has

“Human genes” and patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 14 2013

At 10:00 A.M. on April 15th, the U.S. Supreme Court will entertain oral arguments in the dispute now known as the human "gene patenting" case. The

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy